|
1. Biologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Lowering the GWAS threshold would save millions of dollars [Simply Statistics]
|
|
|
|
|
|
If
Boyle et al. are correct, then hypothesis testing is definitely not an
appropriate statistical approach for GWAS: we know the null hypothesis
is false for most variants. Going forward, to make sense of GWAS data,
we should reinvest the millions of dollars currently used to satisfy the
Bonferroni correction to measure other endpoints and develop new
statistical approaches that can help us understand the molecular cause
of disease and improve treatment outcomes.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5. Traitements
|
|
|
|
Minimizing surgery for melanoma that has spread [NIH]
|
|
|
|
|
|
In
people with melanoma that has spread to a lymph node, immediately
removing all nearby lymph nodes may not extend life. These findings may
change how surgeons make decisions about the initial extent of surgery
for people with melanoma.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
FDA Approves Pembrolizumab for Tumors with Specific Genetic Features [NCI]
|
|
|
|
|
|
Under
FDA’s accelerated approval, the drug manufacturer must verify and
further describe the clinical benefit of the treatment. In one follow-up
trial, called KEYNOTE-177, investigators will compare pembrolizumab
with standard therapy for patients with dMMR or MSI-H colorectal tumors.
The trial is currently recruiting participants.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Worldwide drug sale forecasts fall as pricing pressures mount [Reuters]
|
|
|
|
|
|
Evaluate
Pharma, which compiles consensus numbers based on analysts' forecasts,
said worldwide drug sales were now expected to hit $1.06 trillion in
2022, down from $1.12 trillion predicted a year ago for the same period.
It is the first time in 10 years that total drug sales have failed to
beat the previous year's forecast level.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
6.11 Patients
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.9 Controverses
|
|
|
U.S. Supreme Court ruling threatens massive talc litigation against J&J [Reuters]
|
|
|
|
|
|
On
Monday, the Supreme Court ruled 8-1 in a case involving Bristol-Myers
Squibb Co that state courts cannot hear claims against companies that
are not based in the state when the alleged injuries did not occur
there. The ruling immediately led a St. Louis judge at J&J's urging
to declare a mistrial in the latest talc case, in which two of the three
women at issue were from out of state.
|
|
|
|
|
|